We reviewed the long-term survival, treatment-related mortality and morbidity of a continuous cohort of patients with Hodgkin's disease diagnosed and staged at the Haematology unit of the Belfast City Hospital between January 1973 and October 1992. The analysis included a comparison of the survival of those patients who were entered into BNLI (British National Lymphoma Investigation) trials compared to those not entered during this 20 year period. In addition univariate and multivariate analysis of prognostic factors was performed. The complete remission rate (CR) was 79.6% with a 15 year survival of 55.3%. On multivariate analysis in which deaths due to active Hodgkin's disease only were considered age >50 emerged as the most significant prognostic factor (P<0.0007), the presence of B symptoms also having independent significance (P=0.008). Trial status did not have any independent prognostic significance. Eighty one deaths occurred: active Hodgkin's disease (50), second malignancy (9), treatment-related (10), unrelated (9), unknown (3). This long-term follow up study provides useful information additional to the data produced by clinical trials which are biased by selection criteria. The occurrence of Haemophilus Influenzae meningitis in a patient 17 years following splenectomy highlights the need for appropriate vaccination of patients splenectomised for Hodgkin's disease.
INTRODUCTION
It is now 166 years since Thomas Hodgkin published his original article "On some morbid appearances ofthe absorbentglands and spleen ", in which he described six cases of a condition which he believed to be a specific disease entity. Within the last century Hodgkin's disease has emerged as a curable malignancy due to the efficacy of megavoltage radiotherapy, combination chemotherapy, and more recently marrow ablative chemotherapy followed by stem cell grafting. The survival of patients today has dramatically improved when compared with that of untreated patients, whose five-year survival was reported to be 5.6%.1 With the advent of kilovoltage radiotherapy in the 1920's this figure rose to 51%,2 and a further significant survival increment (73.3% at 5 yrs) resulted from the use of megavoltage radiotherapy in the 1950's.3
Within the last 3 decades the use of combination chemotherapy and combined modality therapy has improved survival with approximately 85% of patients alive at five years.
Such survival data is mainly obtained from the results of clinical trials, which are designed to evaluate different therapeutic regimens in strictly equal patient cohorts, a process which necessitates the use of inclusion/exclusion criteria. This inherent selection process means that clinical trials cannot assess the real survival probability of all patients with a specific disease. For this reason single centre outcome studies are an important means of determining survival outcomes in unselected cohorts of patients. This study was undertaken primarily to ascertain the long-term survival of all patients suffering from Hodgkin's disease who were diagnosed and staged at the Belfast City Hospital over a twenty year period. Secondary objectives were to compare the survival of those patients entered into BNLI trials with those patients who for various reasons were not, to assess the delayed effects oftreatment to identify the various causes of death and to investigate those factors which adversely affected survival in this continuous cohort of unselected patients.
METHODS
We reviewed the case notes of 209 consecutive patients with previously untreated Hodgkin's disease who were diagnosed/staged in the Haematology unit of the Belfast City Hospital from January 1973 to October 1992. One hundred and twelve of these patients had been entered into various BNLI trials, following acceptance of the histological diagnosis by the BNLI panel.
Pathology review
Limited resources prohibited histological review of all the 89 non-trial patient's diagnostic biopsies, but a local panel of pathologists was formed to review the original histology of any of the nontrial patients in situations known to be associated with diagnostic difficulty (i.e. original diagnosis had been made on extranodal tissue, original histology had not been classified using the Rye classification, a second biopsy had questioned the original diagnosis, a second malignancy had been diagnosed simultaneously (within 6 months).) These criteria identified 18 cases for review and with the additional aid of immunocytochemistry a diagnosis of non Hodgkin's lymphoma was favoured in four cases, myeloproliferative disorder in two, and nondiagnostic in two, leaving a total of 201 cases for analysis.
Patients
The characteristics of the patient population (N=201) which includes two sets of siblings are shown in Table I 
RESULTS

Response to treatment
The CR rate was 79.6% (160/201) and the majority of these patients (111) did not relapse. Of the 49 patients (31 %) who relapsed approximately half went on to achieve second CR(25/49). Second relapse occurred in nine of these 25 patients (36%), five of whom successfully achieved third CR, and one patient achieved fourth CR. Patients who achieved CR were significantly younger than non-remitters (P<0.001).
The majority of first relapses (45/49) occurred within five years of the completion of therapy, with only one relapse beyond 10 years and remainder between 5-10 years.
Survival
The overall survival for the 201 patients is shown ( Fig. 1) 
